Using azelaic acid to treat hair loss in women with CCCA
A Pilot Study of Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
This study is testing if azelaic acid can help women with Central Centrifugal Cicatricial Alopecia (CCCA) grow their hair back better than a placebo.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Wake Forest University Health Sciences Academic / other |
| Locations | 1 site (Winston-Salem, North Carolina) |
| Trial ID | NCT05416333 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of azelaic acid as a treatment for Central Centrifugal Cicatricial Alopecia (CCCA) by comparing its effects against a placebo. The study focuses on the anti-inflammatory properties of azelaic acid, which may positively influence the hair growth cycle. Participants will be women aged 18 and older with a clinical diagnosis of CCCA, who have been on stable treatment for at least three months. The study is conducted at Wake Forest Baptist Health, where patients will receive either azelaic acid or usual medication for CCCA.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 18 and older with biopsy-proven or clinically diagnosed CCCA Stage II-IV.
Not a fit: Men and individuals not meeting the specific diagnosis criteria for CCCA will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a new option for women suffering from CCCA, potentially improving hair regrowth and reducing symptoms.
How similar studies have performed: While there is limited research on azelaic acid for CCCA, other anti-inflammatory treatments have shown some success in improving symptoms and hair density in similar conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * women eighteen years of age or older * biopsy-proven and /or clinical diagnosis of CCCA Stage II-IV * on stable treatment without changes for at least three months * recruited from outpatient dermatology clinics at the Wake Forest Baptist Health Department of Dermatology Exclusion Criteria: * males
Where this trial is running
Winston-Salem, North Carolina
- Wake Forest University Health Scieces — Winston-Salem, North Carolina, United States (Recruiting)
Study contacts
- Principal investigator: Amy J McMichael, MD — Wake Forest University Health Sciences
- Study coordinator: Victoria Palmer, MD, MSc
- Email: vpalmer@wakehealth.edu
- Phone: (336)716-3926
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.